<?xml version="1.0" encoding="UTF-8"?>
<p id="P8">Acute and chronic graft-versus-host disease (GVHD) are major causes of non-relapse mortality after alloSCT [
 <xref rid="R7" ref-type="bibr">7</xref>]. Post-transplant maintenance therapy should be well tolerated, with acceptable myelotoxicity and limited drugâ€“drug interactions, and should reduce the incidence or severity of GVHD without impeding graft-versus-leukemia effects [
 <xref rid="R8" ref-type="bibr">8</xref>].
</p>
